|
2017 Conference Publication Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)Kong, G., Grozinsky-Glasberg, S., Callahan, J., Hofman, M., Meirovitz, A., Maimon, O., Pattison, D., Gross, D. and Hicks, R. (2017). Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL). 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, Mar 08-10, 2017. BASEL: KARGER. |
|
2016 Conference Publication PRELIMINARY RESULTS OF (68)GA EXENDIN-4 PET/CT IMAGING OF NEUROENDOCRINE TUMOURS (NETS)Pattison, D., Kong, G., Messazos, B., Hamblin, P., Fourlanos, S., Lee, M., Michael, M., Hong, E., Eu, P. and Hicks, R. (2016). PRELIMINARY RESULTS OF (68)GA EXENDIN-4 PET/CT IMAGING OF NEUROENDOCRINE TUMOURS (NETS). HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication HIGH EFFICACY FROM A PERSONALISED APPROACH USING Y-90-DOTA-OCTREOTATE SEQUENCED WITH (LU)-L-177-DOTA-OCTREOTATE INDUCTION PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT) FOR BULKY NEUROENDOCRINE TUMOURSKong, G., Callahan, J., Hofman, M., Pattison, D., Akhurst, T., Michael, M., Eu, P. and Hicks, R. (2016). HIGH EFFICACY FROM A PERSONALISED APPROACH USING Y-90-DOTA-OCTREOTATE SEQUENCED WITH (LU)-L-177-DOTA-OCTREOTATE INDUCTION PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT) FOR BULKY NEUROENDOCRINE TUMOURS. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)Kong, G., Callahan, J., Hofman, M., Pattison, D., Akhurst, T., Michael, M., Eu, P. and Hicks, R. (2016). Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT). 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, Mar 09-11, 2016. BASEL: KARGER. |
|
2015 Conference Publication MANAGEMENT OF HYPERTENSIVE CRISIS IN PARAGANGLIOMA-A CASE REPORTJackson, Cheryl, Lingaratnam, Senthil, Michael, Michael and Pattison, David (2015). MANAGEMENT OF HYPERTENSIVE CRISIS IN PARAGANGLIOMA-A CASE REPORT. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication IMPROVED SURVIVAL OF POOR PROGNOSIS FDG-AVID NEUROENDOCRINE TUMOURS WITH LU-177 OCTREOTATE PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT)Hofman, M. S., Kashyap, R., Kong, G., Akhurst, T., Pattison, D., Eu, P. and Hicks, R. J. (2015). IMPROVED SURVIVAL OF POOR PROGNOSIS FDG-AVID NEUROENDOCRINE TUMOURS WITH LU-177 OCTREOTATE PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT). HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication GA-68 DOTA-OCTREOTATE (GATATE) AND F-18 FLUORODEOXYGLUCOSE (FDG) PET/CT IN THE ASSESSMENT OF PARAGANGLIOMAS AND PHEOCHROMOCYTOMASChang, C. A., Hofman, M., Thompson, M., Pattison, D. and Hicks, R. (2015). GA-68 DOTA-OCTREOTATE (GATATE) AND F-18 FLUORODEOXYGLUCOSE (FDG) PET/CT IN THE ASSESSMENT OF PARAGANGLIOMAS AND PHEOCHROMOCYTOMAS. HOBOKEN: WILEY-BLACKWELL. |
|
2014 Conference Publication STONES, GROANS AND BONESCrowther, M. and Pattison, D. (2014). STONES, GROANS AND BONES. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication ESTIMATION OF QUANTITATIVE THYROID-TO-BACKGROUND RATIO FOR Tc-99m-SESTAMIBI THYROID SCINTIGRAPHY IN PATIENTS WITH NORMAL THYROID FUNCTIONPattison, David, Westcott, James, Toh, Hock Boon, Lichtenstein, Meir and Sivaratnam, Dinesh (2013). ESTIMATION OF QUANTITATIVE THYROID-TO-BACKGROUND RATIO FOR Tc-99m-SESTAMIBI THYROID SCINTIGRAPHY IN PATIENTS WITH NORMAL THYROID FUNCTION. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication QUANTITATIVE ASSESSMENT OF THYROID-TO-BACKGROUND RATIO IMPROVES THE INTER-OBSERVER RELIABILITY OF 99 m-Tc SESTAMIBI THYROID SCINTIGRAPHY FOR INVESTIGATION OF AMIODARONE-INDUCED THYROTOXICOSISPattison, David, Westcott, James, Lichtenstein, Meir, Toh, Hock Boon, Gunawardana, Dishan, Better, Nathan, Forehan, Simon and Sivaratnam, Dinesh (2013). QUANTITATIVE ASSESSMENT OF THYROID-TO-BACKGROUND RATIO IMPROVES THE INTER-OBSERVER RELIABILITY OF 99 m-Tc SESTAMIBI THYROID SCINTIGRAPHY FOR INVESTIGATION OF AMIODARONE-INDUCED THYROTOXICOSIS. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication APPEARANCE OF 99MTC-SESTAMIBI THYROID SCINTIGRAPHY WITH CALCULATION OF THYROID-TO-BACKGROUND RATIO IN PATIENTS WITH GRAVES' DISEASE, TOXIC MULTINODULAR GOITRE AND HYPOTHYROIDISMPattison, David, Westcott, James, Sivaratnam, Dinesh and Lichtenstein, Meir (2013). APPEARANCE OF 99MTC-SESTAMIBI THYROID SCINTIGRAPHY WITH CALCULATION OF THYROID-TO-BACKGROUND RATIO IN PATIENTS WITH GRAVES' DISEASE, TOXIC MULTINODULAR GOITRE AND HYPOTHYROIDISM. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication PRE-OPERATIVE EVALUATION OF 'AT RISK' MYOCARDIUM WITH INTRACORONARY 99mTc-SESTAMIBI SPECT/CTWestcott, James, Pattison, David, Ajani, Andrew, Antippa, Phillip, Heinze, Stefan, Joshi, Subodh, Lui, Elaine, Langenberg, Francesca and Better, Nathan (2013). PRE-OPERATIVE EVALUATION OF 'AT RISK' MYOCARDIUM WITH INTRACORONARY 99mTc-SESTAMIBI SPECT/CT. HOBOKEN: WILEY-BLACKWELL. |
